Host: |
Rabbit |
Applications: |
WB |
Reactivity: |
Human/Mouse |
Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Short Description: |
Rabbit polyclonal antibody anti-OSMR (100-979) is suitable for use in Western Blot research applications. |
Clonality: |
Polyclonal |
Conjugation: |
Unconjugated |
Isotype: |
IgG |
Formulation: |
PBS with 0.05% Proclin300, 50% Glycerol, pH7.3. |
Purification: |
Affinity purification |
Dilution Range: |
WB 1:500-1:1000 |
Storage Instruction: |
Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles. |
Gene Symbol: |
OSMR |
Gene ID: |
9180 |
Uniprot ID: |
OSMR_HUMAN |
Immunogen Region: |
100-979 |
Immunogen: |
Recombinant fusion protein containing a sequence corresponding to amino acids 100-979 of human OSMR (NP_003990.1). |
Immunogen Sequence: |
ESELPLECATHFVRIKSLVD DAKFPEPNFWSNWSSWEEVS VQDSTGQDILFVFPKDKLVE EGTNVTICYVSRNIQNNVSC YLEGKQIHGEQLDPHVTAFN L |
Tissue Specificity | Expressed in keratinocytes (at protein level). Expressed at relatively high levels in all neural cells as well as fibroblast and epithelial cells. |
Function | Associates with IL31RA to form the IL31 receptor. Binds IL31 to activate STAT3 and possibly STAT1 and STAT5. Capable of transducing OSM-specific signaling events. |
Protein Name | Oncostatin-M-Specific Receptor Subunit BetaInterleukin-31 Receptor Subunit BetaIl-31 Receptor Subunit BetaIl-31r Subunit BetaIl-31r-BetaIl-31rb |
Database Links | Reactome: R-HSA-6788467 |
Cellular Localisation | MembraneSingle-Pass Type I Membrane Protein |
Alternative Antibody Names | Anti-Oncostatin-M-Specific Receptor Subunit Beta antibodyAnti-Interleukin-31 Receptor Subunit Beta antibodyAnti-Il-31 Receptor Subunit Beta antibodyAnti-Il-31r Subunit Beta antibodyAnti-Il-31r-Beta antibodyAnti-Il-31rb antibodyAnti-OSMR antibodyAnti-OSMRB antibody |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance